You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

CLINICAL TRIALS PROFILE FOR SURUFATINIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Surufatinib

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02267967 ↗	Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors	Completed	Hutchison Medipharma Limited	Phase 1	a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
NCT02549937 ↗	A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors	Recruiting	Hutchison Medipharma Limited	Phase 1/Phase 2	Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs), and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD. Secondary Objective: To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients with advanced solid tumors.
NCT02588170 ↗	Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors	Active, not recruiting	Hutchison Medipharma Limited	Phase 3	A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine tumors.
NCT02589821 ↗	Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors	Active, not recruiting	Hutchison Medipharma Limited	Phase 3	A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.
NCT02614495 ↗	Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma	Completed	Hutchison Medipharma Limited	Phase 2	A multi-center , opened, Phase II study to assess the efficacy and safety of Sulfatinib 300 mg Sulfatinib in advanced Medullary Thyroid Carcinoma ( MTC) and iodine-refractory differentiated thyroid carcinoma (DTC).
NCT02966821 ↗	Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma	Completed	Hutchison Medipharma Limited	Phase 2	A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Surufatinib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Neuroendocrine Tumors	7
Biliary Tract Cancer	6
Intrahepatic Cholangiocarcinoma	4
Healthy	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Neuroendocrine Tumors	11
Carcinoma	11
Pancreatic Neoplasms	10
Neoplasms	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Surufatinib

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	81
United States	26
Italy	2
Germany	1
United Kingdom	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	5
Texas	4
Florida	3
Virginia	2
Tennessee	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Surufatinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	19
PHASE1	2
[disabled in preview]	42
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	34
Not yet recruiting	29
NOT_YET_RECRUITING	13
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Surufatinib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Hutchison Medipharma Limited	22
Sun Yat-sen University	11
Fudan University	6
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Other	71
Industry	26
OTHER_GOV	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.